Mark Coles

Mark Coles has a diverse work experience in academia, biotechnology, and research. Mark currently holds the position of Professor and Director of Graduate Studies at the Kennedy Institute of Rheumatology, where they have been working since 2017. In 2019, they also became a Fellow and Theme Lead for Cellular Life at Reuben College, University of Oxford. Coles has made significant contributions to the field of fibroblast biology and severe diseases as a Co-Founder of Mestag Therapeutics, a biotech company they co-founded in 2020. Mark also serves as an Affiliated Faculty at the Mathematical Institute of the University of Oxford since 2020. Previously, Coles co-founded and served as the Director of LightOx, a biotechnology company focused on developing immunotherapeutic approaches for cancer and inflammatory diseases. Mark also co-founded SimOmics, a software company specializing in developing technologies for evidence-based decision-making. Coles has a strong background in immunology and has held various positions at the University of York, including Professor of Immunology, Senior Lecturer, and Lecturer in Immunology. Mark also worked as a Senior Research Scientist at the National Institute for Medical Research and completed their PhD at UC Berkeley. Throughout their career, Coles has been involved in both research and teaching, with a focus on immune development and function, computational modeling, and drug discovery in the fields of cancer, autoimmune diseases, and inflammatory disorders. Mark has also provided consultancy services to pharmaceutical and biotech companies related to immuno-therapeutics.

Mark Coles completed their Bachelor's Degree in Microbiology, General at Cornell University from 1988 to 1992. Mark then pursued higher education at the University of California, Berkeley, where they earned their Doctor of Philosophy (Ph.D.) in Molecular Cell Biology from 1992 to 1998.